A validated UHPLC-MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples

Parker, Suzanne L., Guerra Valero, Yarmarly C., Lipman, Jeffrey, Weiss, Steven, Smith, Camilla, Russell, Lyndal, Smith, Paul, Roberts, Jason A and Wallis, Steven C (2017) A validated UHPLC-MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples. Biomedical Chromatography, 31 12: e4030. doi:10.1002/bmc.4030


Author Parker, Suzanne L.
Guerra Valero, Yarmarly C.
Lipman, Jeffrey
Weiss, Steven
Smith, Camilla
Russell, Lyndal
Smith, Paul
Roberts, Jason A
Wallis, Steven C
Title A validated UHPLC-MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples
Journal name Biomedical Chromatography   Check publisher's open access policy
ISSN 1099-0801
0269-3879
Publication date 2017-12-01
Year available 2017
Sub-type Article (original research)
DOI 10.1002/bmc.4030
Open Access Status Not yet assessed
Volume 31
Issue 12
Start page e4030
Total pages 7
Place of publication Chichester, West Sussex, United Kingdom
Publisher John Wiley & Sons
Language eng
Subject 1602 Analytical Chemistry
1303 Biochemistry
1312 Molecular Biology
3004 Pharmacology
3002 Drug Discovery
1308 Clinical Biochemistry
Abstract Through blocking the cardiac persistent sodium current, riluzole has the potential to prevent myocardial damage post cardiac bypass surgery. A sensitive UHPLC-MS/MS method was developed and validated for quantitation of riluzole and 5-methoxypsoralen in human plasma and myocardial tissue homogenate using a liquid-liquid extraction with dichloromethane. The chromatographic separation was achieved using Shimadzu Shim-pack XR-ODS III, 2.0 × 50 mm, 1.6 μm column with a gradient mobile phase comprising methanol and ammonium acetate buffer pH 3.6 in purified water. The analyte and internal standard were separated within 3.5 min. Riluzole quantitation was achieved using the mass transitions of 235-138 for riluzole and 217-156 for 5-methoxypsoralen. The method was linear for riluzole plasma concentrations from 0.2 to 500 ng/mL and myocardial tissue homogenate concentrations from 0.2 to 100 ng/mL. The method developed was successfully applied to a clinical study for patients receiving riluzole while undergoing cardiac bypass surgery.
Keyword UHPLC-MS/MS
Bio-analysis
Myocardial tissue
Pharmacokinetic
Riluzole
Q-Index Code C1
Q-Index Status Provisional Code
Grant ID APP1048652
APP1099452
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
HERDC Pre-Audit
School of Pharmacy Publications
Admin Only - UQCCR
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Wed, 15 Nov 2017, 13:45:08 EST